|20.82 -0.02 (-0.1%)||12-05 16:00|
|Targets||6-month :||25.12||1-year :||29.35|
|Resists||First :||21.51||Second :||25.12|
|Supports||First :||18.42||Second :||16.52|
|MAs||MA(5) :||20.22||MA(20) :||19.17|
|MA(100) :||22.81||MA(250) :||36.51|
|MACD||MACD :||0.2||Signal :||0|
|%K %D||K(14,3) :||98||D(3) :||94.1|
|52-week||High :||59.99||Low :||16.51|
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ SAGE ] has closed above the upper band by 0.6%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 70.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 70 bars. This is a sign that the market may be about to initiate a new trend.
|If tomorrow:||Open lower||Open higher|
|High:||21 - 21.1||21.1 - 21.17|
|Low:||19.98 - 20.12||20.12 - 20.21|
|Close:||20.62 - 20.83||20.83 - 20.97|
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, treatment resistant disorders, generalized anxiety disorders, and bipolar depression; and SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases. In addition, its product pipeline comprises SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which has completed Phase I clinical trial for the treatment of depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
|Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
|Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
|Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
|Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
|Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
|Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
|Shares Out||0 (M)|
|Shares Float||60 (M)|
|Held by Insiders||4.731e+007 (%)|
|Held by Institutions||12.5 (%)|
|Shares Short||9,870 (K)|
|Shares Short P.Month||0 (K)|
|EPS Est Next Qtrly||0|
|EPS Est This Year||0|
|EPS Est Next Year||0|
|Book Value (p.s.)||0|
|Profit Margin||0 %|
|Operating Margin||-6 %|
|Return on Assets (ttm)||562.9 %|
|Return on Equity (ttm)||-33.8 %|
|Qtrly Rev. Growth||1.135e+007 %|
|Gross Profit (p.s.)||50.17|
|Sales Per Share||-53.33|
|Qtrly Earnings Growth||-11 %|
|Operating Cash Flow||0 (M)|
|Levered Free Cash Flow||-548 (M)|
|Price to Book value||0|
|Price to Sales||-0.4|
|Price to Cash Flow||1.71|
|Dividend Pay Date||Invalid DateTime.|
|Ex-Dividend Date||Invalid DateTime.|